SCHEMBL3625075

SCHEMBL3625075

Cc1csc(NS(=O)(=O)c2cccc(Cl)c2C)n1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 8/20 0.61
HSD17B1 P14061 2/20 0.61
HSD17B2 P37059 2/20 0.61
EDNRB P24530 2/20 0.52
EDNRA P25101 2/20 0.52
KDM1A O60341 2/20 0.52
MAOA P21397 2/20 0.52
SLC40A1 Q9NP59 1/20 0.52
CCR4 P51679 1/20 0.49
ALDH1A1 P00352 1/20 0.47
PKM P14618 1/20 0.47
MAPK1 P28482 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
GAA P10253 1/20 0.45
POLB P06746 2/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5911805 0.86 HSD11B1 (0.58) HSD11B1HSD17B1HSD17B2EDNRBEDNRA
SCHEMBL4963707 0.85 HSD11B1 (0.60) HSD11B1HSD17B1HSD17B2EDNRBEDNRA
SCHEMBL4963665 0.85 HSD11B1 (0.69) HSD11B1HSD17B1HSD17B2EDNRBEDNRA
SCHEMBL5911634 0.85 HSD11B1 (0.57) HSD11B1HSD17B1HSD17B2EDNRBEDNRA
SCHEMBL5911779 0.85 HSD11B1 (0.72) HSD11B1HSD17B1HSD17B2EDNRBEDNRA
SCHEMBL2762518 0.84 KDM1A (0.65) HSD11B1HSD17B1HSD17B2EDNRBEDNRA
SCHEMBL4963995 0.84 HSD11B1 (0.59) HSD11B1HSD17B1HSD17B2EDNRBEDNRA
SCHEMBL7090981 0.84 HSD11B1 (0.67) HSD11B1HSD17B1HSD17B2EDNRBEDNRA
SCHEMBL3622382 0.84 HSD11B1 (0.59) HSD11B1HSD17B1HSD17B2EDNRBEDNRA
SCHEMBL2762614 0.84 KDM1A (0.69) HSD11B1HSD17B1HSD17B2KDM1AMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060287374-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB 2006-12-21 US claimed
US-7125900-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2006-10-24 US claimed
WO-2004112781-A1 NEW USE II BIOVITRUM AB (SE) 2004-12-29 WO claimed
US-20030176476-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2003-09-18 US claimed
US-20100113435-A1 INHIBITORS OF 11-BETA-HYDROXY STERIOD DEHYDROGENASE TYPE 1 BIOVITRUM AB 2010-05-06 US disclosed
US-7618961-B2 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2009-11-17 US disclosed
US-20060287374-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB 2006-12-21 US disclosed
US-7125900-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2006-10-24 US disclosed
WO-2004112781-A1 NEW USE II BIOVITRUM AB (SE) 2004-12-29 WO disclosed
US-20040224996-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2004-11-11 US disclosed
US-20030176476-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2003-09-18 US disclosed
EP-1283831-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-02-19 EP disclosed
EP-1283833-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-02-19 EP disclosed
WO-2001090091-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2001-11-29 WO disclosed
WO-2001090090-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2001-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176476-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD11B2 HSD11B1 1/4885HSD17B1 2/4885HSD17B2 6/4885
US-20040224996-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD11B2 HSD11B1 1/4885HSD17B1 2/4885HSD17B2 5/4885
US-20060287374-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD11B2 HSD11B1 1/4885HSD17B1 2/4885HSD17B2 6/4885
US-20100113435-A1 INHIBITORS OF 11-BETA-HYDROXY STERIOD DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD3B1 HSD11B1 1/4885HSD17B1 2/4885HSD17B2 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.